Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.67 |
| ▸ | DNMT3A | Q9Y6K1 | 6/20 | 0.67 |
| ▸ | CCR4 | P51679 | 1/20 | 0.64 |
| ▸ | NSD2 | O96028 | 3/20 | 0.62 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941306 | 1.00 | EHMT2 (0.74) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941067 | 0.99 | EHMT2 (0.72) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941171 | 0.90 | DNMT3A (0.81) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941071 | 0.90 | EHMT2 (0.75) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941331 | 0.90 | EHMT2 (0.77) | EHMT2DNMT3ANSD2NSD3EHMT1 | |
| SCHEMBL14940958 | 0.89 | DNMT3A (0.65) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941385 | 0.89 | EHMT2 (0.76) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL18932090 | 0.89 | DNMT3A (0.65) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941378 | 0.89 | DNMT3A (0.68) | EHMT2LMNAMAPTHTTKMT2A | |
| SCHEMBL14941303 | 0.86 | EHMT2 (0.76) | EHMT2LMNAMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | claimed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | claimed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | claimed |
| WO-2013070852-A2 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | claimed |
| EP-2828250-B1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-10828331-B2 | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto | EMORY UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828331-B2 | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto | EMORY UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20170157178-A1 | Cellular Compositions Used To Restore Stem Cell or Progenitor Cell Function and Methods Related Thereto | UNIV EMORY (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157178-A1 | Cellular Compositions Used To Restore Stem Cell or Progenitor Cell Function and Methods Related Thereto | UNIV EMORY (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157178-A1 | Cellular Compositions Used To Restore Stem Cell or Progenitor Cell Function and Methods Related Thereto | UNIV EMORY (US) | 2017-06-08 | — | — | US | disclosed |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013140148-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013070852-A2 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828331-B2 | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto | BMI1, DNMT1, DNMT3A | EHMT2 8/4885LMNA 857/4885MAPT 3430/4885 |
| US-20170157178-A1 | Cellular Compositions Used To Restore Stem Cell or Progenitor Cell Function and Methods Related Thereto | BMI1, DNMT1, DNMT3A | EHMT2 8/4885LMNA 857/4885MAPT 3430/4885 |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | BMI1, DNMT3L, DNMT3B | EHMT2 8/4885LMNA 983/4885MAPT 2598/4885 |
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | BMI1, DNMT1, DNMT3A | EHMT2 8/4885LMNA 857/4885MAPT 3430/4885 |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | EZH2, EHMT1, HNMT | EHMT2 4/4885LMNA 2848/4885MAPT 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.